Australian Group on Antimicrobial Resistance (AGAR) Australian Gram-negative Sepsis Outcome Programme (GNSOP) Annual Report 2017

Jan M Bell, Thomas Gottlieb, Denise A Daley and Geoffrey W Coombs

# Abstract

The Australian Group on Antimicrobial Resistance (AGAR) performs regular period-prevalence studies to monitor changes in antimicrobial resistance in selected enteric Gram-negative pathogens. The 2017 survey was the fifth year to focus on blood stream infections, and included Enterobacterales, Pseudomonas aeruginosa and Acinetobacter species.

Seven thousand nine hundred and ten isolates, comprising Enterobacterales (7,100, 89.8%), P. aeruginosa (697, 8.8%) and Acinetobacter species (113, 1.4%), were tested using commercial automated methods. The results were analysed using Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints (January 2018). Of the key resistances, non-susceptibility to the third-generation cephalosporin, ceftriaxone, was found in 11.3%/11.3% of Escherichia coli (CLSI/EUCAST criteria), 8.8%/8.8% of Klebsiella pneumoniae, and 5.7%/5.7% of K. oxytoca. Non-susceptibility rates to ciprofloxacin were 12.1%/18.0% for E. coli, 4.4%/11.2% for K. pneumoniae, 1.3%/3.5% for K. oxytoca, 3.0%/8.5% for Enterobacter cloacae complex, and 5.1%/9.8% for P. aeruginosa. Resistance rates to piperacillin-tazobactam were 2.8%/5.9%, 3.7%/7.3%, 9.6%/11.0%, 22.5%/27.6%, and 6.4%/13.2% for the same five species respectively. Twenty-seven isolates from 25 patients were shown to harbour a carbapenemase gene: 12 blaIMP (11 patients), five blaOXA-181 (four patients), three blaOXA-23, two blaNDM, two blaKPC, two blaVIM, and one blaGES.

Keywords: Australian Group on Antimicrobial Resistance (AGAR); antibiotic resistance; bacteraemia; gram-negative; Escherichia coli; Enterobacter; Klebsiella

# Introduction

Emerging resistance in common pathogenic members of the Enterobacterales is a world-wide phenomenon and presents therapeutic problems for practitioners, both in the community and in hospital practice. The Australian Group on Antimicrobial Resistance (AGAR) commenced surveillance of the key Gram-negative pathogens, Escherichia coli and Klebsiella species in 1992. Surveys have been conducted biennially until 2008 when annual surveys commenced, alternating between community- and hospital-onset infections (http://www.agargroup.org/surveys). In 2004, another genus of Gram-negative pathogens in which resistance can be of clinical importance, Enterobacter species, was added. E. coli is the most common cause of community-onset urinary tract infection; Klebsiella species are less common but are known to harbour important resistances. Enterobacter species are less common in the community, but of high importance due to intrinsic resistance to first-line antimicrobials in the community. Taken together, the three groups of species surveyed are considered to be valuable sentinels for multi-resistance and emerging resistance in enteric Gram-negative bacilli. In 2013 AGAR commenced the Enterobacteriaceae Sepsis Outcome Programme (EnSOP) which focused on the collection of resistance and some demographic data on all isolates prospectively from patients with bacteraemia. In 2015, Pseudomonas aeruginosa and Acinetobacter species were added, and the program referred to as the Gram-negative Sepsis Outcome Program (GNSOP).

Resistances of particular interest include resistance to ß-lactams due to ß-lactamases, especially extended-spectrum ß-lactamases, which inactivate the third-generation cephalosporins that are normally considered reserve antimicrobials. Other resistances of interest are to agents important for treatment of these serious infections, such as gentamicin; and resistance to reserve agents such as ciprofloxacin, meropenem and colistin.

The objectives of the 2017 surveillance program were to:

* Monitor resistance in Enterobacterales, P. aeruginosa and Acinetobacter species isolated from blood cultures taken from patients presenting to the hospital or already in hospital
* Examine the extent of co-resistance and multidrug resistance in the major species
* Detect emerging resistance to newer last-line agents such as carbapenems
* Characterise the molecular basis of resistance to third-generation cephalosporins, quinolones, amikacin and carbapenems

# Methods

## Study design

From 1 January to 31 December 2017, 36 laboratories across Australia collected either all or up to 200 isolates from different patient episodes of bacteraemia.

## Species identification

Isolates were identified using the routine method for each institution; Vitek®, Phoenix™ Automated Microbiology System, or where available mass spectrometry (MALDI-ToF).

## Susceptibility testing

Testing was performed by two commercial semi-automated methods, Vitek 2 (BioMérieux, France) or Phoenix (Becton Dickinson, USA), which are calibrated to the ISO reference standard method of broth microdilution. Commercially available Vitek AST-N246 and AST-N247, or Phoenix NMIC-203 and NIMC-404 cards were utilized by all participants throughout the survey period. The CLSI M1001 and EUCAST v8.02 breakpoints from January 2018 have been employed in the analysis. For analysis of cefazolin, breakpoints of ≤4 mg/L for susceptible, ≥ 8 mg/L for resistant were applied due to the restricted minimum inhibitory concentration (MIC) range available on the commercial cards, recognising that the January 2018 breakpoint is actually susceptible ≤2 mg/L.

## Molecular confirmation of resistances

E. coli, Klebsiella spp., Proteus spp. and Salmonella spp. with ceftazidime or ceftriaxone MIC > 1 mg/L, or cefoxitin MIC > 8 mg/L; any other Enterobacterales with cefepime MIC > 1 mg/L; all isolates with ciprofloxacin MIC > 0.25 mg/L; all isolates with meropenem MIC > 0.25 mg/L; all isolates with amikacin MIC > 32 mg/L, and all isolates with colistin MIC > 2 mg/L were referred to a central laboratory (University of Adelaide) for molecular confirmation of resistance.

All referred isolates were screened using real-time polymerase chain reaction (PCR) platform (LC-480) and published primers for the presence of blaTEM and blaSHV, CTX-M-type genes (groups 1, 2, 9, 8/25), plasmid-borne AmpC (blaCIT, blaDHA, blaEBC, blaACC, blaFOX, blaMOX), and carbapenemases genes (blaIMP, blaNDM, blaKPC, blaOXA-48-like, blaVIM, blaGES, blaSME, blaIMI).3–5

PCRs was also used to detect blaIMP types, known plasmid-mediated quinolone resistance mechanisms (qnr, efflux [qepA, oqxAB] and aac (6’)-Ib-cr), aminoglycoside ribosomal methyltransferases (armA, rmtB, rmtC, rmtF), and mobile colistin resistance genes (mcr-1, mcr-2, mcr-3).6–11 All referred E. coli were examined for membership of the O25b-ST131 clone.12 All isolates with demonstrated carbapenemase activity and any amikacin resistant isolates were also screened for OXA-23-like, -24, and -58 carbapenemases.13

All isolates with carbapenemase activity were subjected to whole genome sequencing using the Illumina MiSeq platform. Data were analysed using the Nullarbor bioinformatic pipeline.14 The pipeline was used to identify the multi-locus sequence type and the resistome.

# Results

The species isolated, and the numbers of each are listed in Table 1. Enterobacterales accounted for 89.8%, followed by P. aeruginosa (8.8%) and Acinetobacter species (1.4%). Of the Enterobacterales, three genera—Escherichia (61.6%), Klebsiella (19.9%) and Enterobacter (6.3%)—contributed 87.8% of all isolates. Major resistances and non-susceptibilities for the top six ranked species are listed in Table 2. Non-susceptibility (which includes both intermediately resistant and resistant isolates) has been included for some agents because these figures provide information about important emerging acquired resistances. Multiple acquired resistances by species are shown in Table 3. Multi-resistance was detected in 21.9% of E. coli isolates, 10.4% of K. pneumoniae, and 18.6% of E. cloacae complex. A more detailed breakdown of resistances and non-susceptibilities by state and territory is provided in the online AGAR report.

Table 1. Number and proportion of species isolated, blood cultures, 2017

| Species | Percentage (n) |
| --- | --- |
| *Escherichia coli* | 55.2 (4,370) |
| *Klebsiella pneumoniae* | 12.7 (1,001) |
| *Pseudomonas aeruginosa* | 8.8 (697) |
| *Enterobacter cloacae* complex | 5.5 (433) |
| *Proteus mirabilis* | 3.0 (235) |
| *Klebsiella oxytoca* | 2.9 (229) |
| *Serratia marcescens* | 2.1 (167) |
| *Salmonella* species (non-typhoidal) | 1.7 (134) |
| *Klebsiella aerogenes* | 1.3 (105) |
| *Morganella morganii* | 1.1 (85) |
| *Klebsiella variicola* | 0.9 (72) |
| *Acinetobacter baumannii* complex | 0.8 (65) |
| *Citrobacter freundii* | 0.7 (56) |
| *Citrobacter koseri* | 0.5 (43) |
| *Salmonella* species (typhoidal) | 0.4 (31) |
| *Raoultella ornithinolytica* | 0.2 (14) |
| *Pantoea agglomerans* | 0.2 (14) |
| *Acinetobacter* species | 0.2 (12) |
| *Acinetobacter lwoffii* | 0.1 (11) |
| Other species (total n = 42) | 1.7 (136) |
| Total | 7,910 |

Table 2. Non-susceptibility and resistance rates for the top six ranked species tested, 2017

|  |  | *E. coli*(%) | *K. pneumoniae*(%) | *P. aeruginosa*(%) | *E. cloacae complex*(%) | *K. oxytoca*(%) | *P. mirabilis*(%) |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Antimicrobial | Categorya | CLSI | EUCAST | CLSI | EUCAST | CLSI | EUCAST | CLSI | EUCAST | CLSI | EUCAST | CLSI | EUCAST |
| Ampicillin | I | 1.4 | – | *b* | *b* | na | na | *b* | *b* | *b* | *b* | 0.4 | - |
| R | 53.0 | 54.4 | *b* | *b* | na | na | *b* | *b* | *b* | *b* | 16.6 | 17.0 |
| Amoxicillin-clavulanic acid (2:1)c | I | 13.6 | na | 4.1 | – | na | na | *b* | *b* | 3.5 | – | 5.5 | – |
| R | 8.4 | – | 5.3 | – | na | na | *b* | *b* | 8.3 | – | 2.6 | – |
| Piperacillin-tazobactam | R | 2.8 | 5.9 | 3.7 | 7.3 | 6.4 | 13.2 | 22.5 | 27.6 | 9.6 | 11.0 | 0.0 | 1.3 |
| Cefazolin | R | 22.8 | 22.8 | 12.5 | 12.5 | na | na | *b* | *b* | 67.1 | 67.1 | 18.5 | 18.5 |
| Cefoxitin | R | 3.7 | / | 5.6 | / | na | na | *b* | *b* | 2.2 | / | 0.4 | / |
| Ceftriaxone | NS | 11.3 | 11.3 | 8.8 | 8.8 | na | na | 27.9 | 27.9 | 5.7 | 5.7 | 2.1 | 2.1 |
| Ceftazidime | NS | 6.3 | 11.1 | 5.8 | 8.6 | 9.3 | 9.3 | 24.9 | 28.2 | 0.0 | 0.4 | 1.3 | 3.0 |
| Cefepime | NS | 5.1 | 8.7 | 4.0 | 6.9 | 3.3 | 6.5 | 6.9 | 14.5 | 0.4 | 0.9 | 1.3 | 1.3 |
| Meropenem | NS | 0.1 | 0.1 | 0.8 | 0.8 | 7.9 | 7.9 | 2.3 | 2.3 | 0.0 | 0.0 | 0.0 | 0.0 |
| Ciprofloxacin | NS | 12.1 | 18.0 | 4.4 | 11.2 | 5.1 | 9.8 | 3.0 | 8.5 | 1.3 | 3.5 | 3.4 | 6.8 |
| Gentamicin | R | 8.4 | 8.5 | 4.4 | 4.9 | 2.0 | 3.9 | 6.9 | 7.4 | 0.4 | 0.4 | 3.4 | 4.7 |
| Trimethoprim–sulfamethoxazole | R | 31.2 | 31.1 | 16.1 | 15.7 | na | na | 20.1 | 19.9 | 3.5 | 3.5 | 14.9 | 14.9 |
| Nitrofurantoin | R | 0.8 | 0.8 | 23.1 | / | na | na | 10.6 | / | 1.8 | / | *b* | *b* |

a R = resistant, I = intermediate, NS = non-susceptible (intermediate + resistant), using criteria as published by the CLSI [2018] and EUCAST [2018].

b Considered largely intrinsically resistant due to natural β-lactamases; – no intermediate category; / no breakpoints defined; na = not applicable (testing not recommended)

c For EUCAST interpretation, the clavulanate is fixed at 2 mg/L, rather than a 2:1 ratio used in CLSI guidelines. As all susceptibility test cards used have a 2:1 ratio of clavulanate no EUCAST category has been applied.

Table 3. Multiple acquired resistances by species, 2017

|  | Number of acquired resistances (EUCAST breakpoints) |
| --- | --- |
|  |  | Non-multi-resistant |  | Multi-resistant |  |
| Species | Total | 0 | 1 | 2 | 3 | Cumulative% | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | Cumulative% |
| *E. coli* | 4,293 | 1,688 | 636 | 669 | 360 |  | 268 | 189 | 125 | 134 | 100 | 71 | 41 | 12 | 0 | 0 |  |
| % | 39.3 | 14.8 | 15.6 | 8.4 | 78.1 | 6.2 | 4.4 | 2.9 | 3.1 | 2.3 | 1.7 | 1.0 | 0.3 | 0.0 | 0.0 | 21.9 |
| *K. pneumoniae*a | 983 | 701 | 114 | 40 | 26 |  | 19 | 11 | 12 | 19 | 10 | 26 | 4 | 1 | na | na |  |
| % | 71.3 | 11.6 | 4.1 | 2.6 | 89.6 | 1.9 | 1.1 | 1.2 | 1.9 | 1.0 | 2.6 | 0.4 | 0.1 |  |  | 10.4 |
| *E. cloacae complex*b | 350 | 199 | 36 | 11 | 39 |  | 30 | 8 | 14 | 6 | 5 | 2 | na | na | na | na |  |
| % | 56.9 | 10.3 | 3.1 | 11.1 | 81.4 | 8.6 | 2.3 | 4.0 | 1.7 | 1.4 | 0.6 |  |  |  |  | 18.6 |
| *P. mirabilis* | 231 | 130 | 57 | 14 | 12 |  | 8 | 4 | 2 | 1 | 0 | 3 | 0 | 0 | 0 | na |  |
| % | 56.3 | 24.7 | 6.1 | 5.2 | 92.2 | 3.5 | 1.7 | 0.9 | 0.4 | 0.0 | 1.3 | 0.0 | 0.0 | 0.0 |  | 7.8 |
| *K. oxytoca*a | 221 | 59 | 115 | 19 | 16 |  | 8 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | na | na |  |
| % | 26.7 | 52.0 | 8.6 | 7.2 | 94.6 | 3.6 | 1.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |  |  | 5.4 |
| *Salmonella* species (non-typhoidal) | 127 | 110 | 14 | 2 | 0 |  | 1 | 0 | 0 | 0 | 0 | 0 | na | na | na | na |  |
| % | 86.6 | 11.0 | 1.6 | 0.0 | 99.2 | 0.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |  |  |  |  | 0.8 |
| *S. marcescens*b | 126 | 115 | 5 | 4 | 2 |  | 0 | 0 | 0 | 0 | 0 | 0 | na | na | na | na |  |
| % | 91.3 | 4.0 | 3.2 | 1.6 | 100 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |  |  |  |  | 0.0 |
| *K. aerogenes*b | 102 | 48 | 8 | 3 | 35 |  | 6 | 1 | 0 | 1 | 0 | 0 | na | na | na | na |  |
| % | 47.1 | 7.8 | 2.9 | 34.3 | 92.2 | 5.9 | 1.0 | 0.0 | 1.0 | 0.0 | 0.0 |  |  |  |  | 7.8 |

a Antibiotics included: amoxicillin-clavulanate, piperacillin-tazobactam, cefazolin, cefoxitin, ceftriaxone, ceftazidime, cefepime, gentamicin, amikacin, ciprofloxacin, nitrofurantoin, trimethoprim, meropenem; na = not applicable
Antibiotics excluded: ampicillin (intrinsic resistance), tobramycin, norfloxacin, nalidixic acid, trimethoprim-sulfamethoxazole (high correlation with antibiotics in the included list)

b Antibiotics included: piperacillin-tazobactam, ceftriaxone, ceftazidime, cefepime, gentamicin, amikacin, ciprofloxacin, trimethoprim, meropenem
Antibiotics excluded: ampicillin, amoxicillin-clavulanate, cefazolin, and cefoxitin (all four due to intrinsic resistance); also excluded were ticarcillin-clavulanate, tobramycin, norfloxacin, nalidixic acid, trimethoprim-sulfamethoxazole (high correlation with antibiotics in the included list).

## **Escherichia coli**

Moderately high levels of resistance to ampicillin (and therefore amoxicillin) were maintained (53.0%/54.4%, CLSI/EUCAST criteria), with lower rates for amoxicillin-clavulanic acid (13.6%/– intermediate, 8.4%/– resistant). Non-susceptibility to third-generation cephalosporins was low (ceftriaxone 11.3%/11.3%, ceftazidime 6.3%/11.1%). Moderate levels of resistance were detected to cefazolin (22.8%/22.8%) and trimethoprim–sulfamethoxazole (31.2%/31.2%). Ciprofloxacin non-susceptibility was found in 12.1%/18.0% of E. coli isolates. Resistance to gentamicin (8.4%/8.5%), piperacillin-tazobactam (2.8%/5.9%) and cefepime (5.1%/8.7%) was low. Eleven isolates (0.3%) had elevated meropenem MICs (≥ 0.5 mg/L). For the strains with extended-spectrum β-lactamase (ESBL) phenotype, ciprofloxacin and gentamicin resistance was found in 56.5%/64.2% and 35.5%/35.6% respectively.

Most of the E. coli strains with ESBL genes harboured genes of the CTX-M type (408/536 = 76%). Fifty-three percent of E. coli with CTX-M group 1 types were found to belong to sequence type 131 (O25b-ST131). ST131 accounted for 57% of E. coli ESBL phenotypes that were ciprofloxacin resistant (MIC >1 mg/L), and only 5% of ciprofloxacin susceptible ESBL phenotypes.

## **Klebsiella pneumoniae**

K. pneumoniae showed slightly higher levels of resistance to piperacillin-tazobactam compared with E. coli, but lower rates of resistance to amoxicillin-clavulanic acid, cefazolin, ceftriaxone, ceftazidime, ciprofloxacin, gentamicin, and trimethoprim-sulfamethoxazole. Ten (1.0%) K. pneumoniae isolates had elevated meropenem MICs (see below). ESBLs were present in 77 of 95 (81%) presumptively ESBL-positive isolates of K. pneumoniae, 67 (87%) of which were confirmed to be of the CTX-M type.

## **Enterobacter cloacae** complex

Acquired resistance was common to piperacillin-tazobactam (22.5%/27.6%) ceftriaxone (27.9%/27.9%), ceftazidime (24.9%/28.2%) and trimethoprim–sulfamethoxazole (20.1%/19.9%) among E. cloacae complex isolates. Cefepime resistance was less than 15%; ciprofloxacin and gentamicin resistance were both less than 10%. Twenty-one (4.9%) E. cloacae complex strains had elevated meropenem MICs.

## Carbapenemase resistance

Overall, 27 isolates (25 patients) in thirteen institutions from five states/territories were found to harbour a carbapenemase gene. blaIMP-4 was detected in 12 isolates: E. cloacae (eight), K. pneumoniae (three), and E. coli (one) – one E. cloacae and one K. pneumoniae were from the same patient. blaOXA-181 was detected in four E. coli and one K. pneumoniae – one E. coli and one K. pneumoniae from the same patient. blaOXA-23 was detected in three A. baumannii; blaNDM-1 was detected in two K. pneumoniae; blaKPC-2 was detected in one K. pneumoniae and blaKPC-3 in one E. coli; blaVIM-1 was detected in one E. cloacae and blaVIM-5 in one P. aeruginosa; and blaGES-5 was detected in one P. aeruginosa.

# Discussion

AGAR has been tracking resistance in sentinel enteric Gram-negative bacteria since 1992. From 2008, surveillance was segregated into hospital- versus community-onset infections. The last year of hospital-onset only surveillance was 2011.15 In 2013, the first survey of antimicrobial resistance among Enterobacterales isolates from bacteraemic patients through Australia was conducted using an approach similar to that conducted by the European EARS-Net program. 2017 was the fifth survey of antimicrobial resistance among Enterobacterales, and the third for P. aeruginosa and Acinetobacter spp. from bacteraemic patients through Australia.

CTX-M-producing E. coli and Klebsiella species and gentamicin- and ciprofloxacin-resistant E. coli continued to be a problem in patients with bacteraemia. Of concern is the high proportion of E. coli that belong to the O25b-ST131 clone. Carbapenem resistance attributable to acquired carbapenemases are still uncommon in patients with bacteraemia in Australia, although seven different types (IMP, KPC, NDM, OXA-181, OXA-23, VIM, and GES) were detected from thirteen of the participating institutions. Compared with many other countries in our region, resistance rates in Australian Gram-negative bacteria are still relatively low,16 but similar to those observed in 2017 in many Western European countries.17

Multi-resistance is being increasingly observed, especially in E. coli and E. cloacae complex, both of which have multi-resistance rates (as defined by AGAR) above 18%. This is likely to drive more broad-spectrum antibiotic use, and increase the resistance selection pressure for important reserve classes, especially the carbapenemases.

# Acknowledgments

This study was funded by a grant from the Australian Commission on Safety and Quality in Healthcare.

Members of the AGAR in 2017 were:

## Australian Capital Territory

Peter Collignon and Susan Bradbury, Canberra Hospital

## New South Wales

Thomas Gottlieb and Graham Robertson, Concord Hospital

Rodney Givney and Ian Winney, John Hunter Hospital

James Branley and Linda Douglass, Nepean Hospital

Peter Huntington, Royal North Shore Hospital

Sebastiaan van Hal and Alicia Beukers, Royal Prince Alfred Hospital

Jock Harkness and David Lorenz, St Vincent’s Hospital Sydney

Jon Iredell and Andrew Ginn, Westmead Hospital

Peter Newton and Melissa Hoddle, Wollongong Hospital

## Northern Territory

James McLeod, Alice Springs Hospital

Rob Baird and Jann Hennessy, Royal Darwin Hospital

## Queensland

Enzo Binotto and Bronwyn Thomsett, Pathology Queensland Cairns Base Hospital

Graeme Nimmo and Narelle George, Pathology Queensland Central Laboratory, Royal Brisbane and Women’s Hospital

Clare Nourse Pathology Queensland Lady Cilento Children’s Hospital

Petra Derrington and Cheryl Curtis, Pathology Queensland Gold Coast Hospital

Robert Horvath and Laura Martin, Pathology Queensland Prince Charles Hospital

Naomi Runnegar and Joel Douglas, Pathology Queensland Princess Alexandra Hospital

Jennifer Robson and Georgia Peachey, Sullivan Nicolaides Pathology

## South Australia

Kelly Papanaoum and Xiao Ming Chen, SA Pathology, Flinders Medical Centre

Morgyn Warner and Kija Smith, SA Pathology, Royal Adelaide Hospital and Women’s and Children’s Hospital

## Tasmania

Pankaja Kalukottege and Kathy Wilcox, Launceston General Hospital

Louise Cooley and David Jones, Royal Hobart Hospital

## Victoria

Denis Spelman and Rose Bernhard, Alfred Hospital

Paul Johnson and Frances Hurren, Austin Health

Tony Korman and Despina Kotsanas, Monash Health, Monash Medical Centre and Monash Children’s Hospital

Andrew Daley and Gena Gonis, Royal Women’s and Children’s Hospital

Mary Jo Waters and Lisa Brenton, St Vincent’s Hospital

## Western Australia

Shalinie Perera and Ian Meyer, Western Diagnostic Pathology, Joondalup Hospital

David McGechie and Denise Daley, PathWest Laboratory Medicine WA, Fiona Stanley Hospital

Chris Blyth, PathWest Laboratory Medicine WA, Princess Margaret Hospital for Children

Ronan Murray and Jacinta Bowman, PathWest Laboratory Medicine WA, Sir Charles Gairdner Hospital

Michael Leung, PathWest Laboratory Medicine WA, Northwest WA

Owen Robinson and Geoffrey Coombs, PathWest Laboratory Medicine WA, Royal Perth Hospital

Sudha Pottumarthy-Boddu and Fay Kappler, Australian Clinical Laboratories, St John of God Hospital Murdoch

# Author details

Ms Jan M Bell1

A /Prof Thomas Gottlieb2

Ms Denise A Daley3

Prof Geoffrey W Coombs4,5

1. University of Adelaide, Adelaide, South Australia, Australia
2. Concord Hospital, Concord, New South Wales, Australia
3. Australian Group on Antimicrobial Resistance, Fiona Stanley Hospital, Murdoch, Western Australia, Australia
4. Antimicrobial Resistance and Infectious Diseases (AMRID) Research Laboratory, Murdoch University, Murdoch, Western Australia, Australia
5. Department of Microbiology, PathWest Laboratory Medicine-WA, Fiona Stanley Hospital, Murdoch, Western Australia, Australia

## Corresponding Author

A/Prof Thomas Gottlieb Telephone: (02) 9767 7533 Email: thomas.gottlieb@health.nsw.gov.au

# References

1. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 28th ed. CLSI supplement M100. Clinical and Laboratory Standards Institute, Wayne, Pennsylvania, USA; 2018.
2. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 8.0, January 2018. [Accessed 1 January 2018.] Available at http://www.eucast.org/clinical\_breakpoints/ .
3. Ellington MJ, Findlay J, Hopkins KL, Meunier D, Alvarez-Buylla A, Horner C, et al. Multicentre evaluation of a real-time PCR assay to detect genes encoding clinically relevant carbapenemases in cultured bacteria. Int J Antimicrob Agents. 2016;47(2):151–4.
4. Roschanski N, Fischer J, Guerra B, Roesler U. Development of a multiplex real-time PCR for the rapid detection of the predominant beta-lactamase genes CTX-M, SHV, TEM and CIT-type AmpCs in Enterobacteriaceae. PLoS One. 2014;9(7):e100956.
5. Swayne R, Ellington MJ, Curran MD, Woodford N, Aliyu SH. Utility of a novel multiplex TaqMan PCR assay for metallo-β-lactamase genes plus other TaqMan assays in detecting genes encoding serine carbapenemases and clinically significant extended-spectrum β-lactamases. Int J Antimicrob Agents. 2013;42(4):352–6.
6. Ciesielczuk H, Hornsey M, Choi V, Woodford N, Wareham DW. Development and evaluation of a multiplex PCR for eight plasmid-mediated quinolone-resistance determinants. J Med Microbiol. 2013;62(Pt 12):1823–7.
7. Corrêa LL, Montezzi LF, Bonelli RR, Moreira BM, Picão RC. Revised and updated multiplex PCR targeting acquired 16S rRNA methyltransferases. Int J Antimicrob Agents. 2014;43(5):479–81.
8. Doi Y, Arakawa Y. 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. Clin Infect Dis. 2007;45(1):88–94.
9. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16(2):161–8.
10. Mendes RE, Kiyota KA, Monteiro J, Castanheira M, Andrade SS, Gales AC et al. Rapid detection and identification of metallo-beta-lactamase-encoding genes by multiplex real-time PCR assay and melt curve analysis. J Clin Microbiol. 2007;45(2):544–7.
11. Yin W, Li H, Shen Y, Liu Z, Wang S, Shen Z et al. Novel plasmid-mediated colistin resistance gene mcr-3 in Escherichia coli. MBio. 2017;8(3). pii: e00543-17.
12. Dhanji H, Doumith M, Clermont O, Denamur E, Hope R, Livermore DM et al. Real-time PCR for detection of the O25b-ST131 clone of Escherichia coli and its CTX-M-15-like extended-spectrum beta-lactamases. Int J Antimicrob Agents. 2010;36(4):355–8.
13. Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents. 2006;27(4):351–3.
14. Seemann T, Goncalves da Silva A, Bulach DM, Schultz MB, Kwong JC, Howden BP. Nullarbor. San Francisco; Github. Available from: https://github.com/tseemann/nullarbor .
15. Turnidge J, Gottlieb T, Mitchell D, Pearson J, Bell J, for the Australian Group for Antimicrobial Resistance. Gram-negative Survey 2011 Antimicrobial Susceptibility Report. Adelaide; 2011. Available from: http://www.agargroup.org/files/AGAR20GNB0820Report20FINAL.pdf
16. Sheng WH, Badal RE, Hsueh PR; SMART Program. Distribution of extended-spectrum β-lactamases, AmpC β-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother. 2013;57(7):2981–8.
17. European Centre for Disease Prevention and Control (ECDC). Surveillance of antimicrobial resistance in Europe 2017. [Internet.] European Centre for Disease Prevention and Control; 2018. Available from: https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2017

**Communicable Diseases Intelligence**

ISSN: 2209-6051 Online

**Communicable Diseases Intelligence (CDI) is a peer-reviewed scientific journal published by the Office of Health Protection, Department of Health. The journal aims to disseminate information on the epidemiology, surveillance, prevention and control of communicable diseases of relevance to Australia.**

**Editor:** Cindy Toms

**Deputy Editor:** Simon Petrie

**Design and Production:** Kasra Yousefi

**Editorial Advisory Board:** David Durrheim, Mark Ferson, John Kaldor, Martyn Kirk and Linda Selvey

**Website**: <http://www.health.gov.au/cdi>

**Contacts**Communicable Diseases Intelligence is produced by:
Health Protection Policy Branch, Office of Health Protection, Australian Government Department of Health
GPO Box 9848, (MDP 6) CANBERRA ACT 2601

**Email:** cdi.editor@health.gov.au

**Submit an Article**You are invited to submit your next communicable disease related article to the Communicable Diseases Intelligence (CDI) for consideration. More information regarding CDI can be found at: <http://health.gov.au/cdi>.

Further enquiries should be directed to: cdi.editor@health.gov.au.

This journal is indexed by Index Medicus and Medline.

Creative Commons Licence - Attribution-NonCommercial-NoDerivatives CC BY-NC-ND

© 2019 Commonwealth of Australia as represented by the Department of Health

This publication is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence from <https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode> (Licence). You must read and understand the Licence before using any material from this publication.

**Restrictions**The Licence does not cover, and there is no permission given for, use of any of the following material found in this publication (if any):

* the Commonwealth Coat of Arms (by way of information, the terms under which the Coat of Arms may be used can be found at [www.itsanhonour.gov.au](http://www.itsanhonour.gov.au/));
* any logos (including the Department of Health’s logo) and trademarks;
* any photographs and images;
* any signatures; and
* any material belonging to third parties.

**Disclaimer**Opinions expressed in Communicable Diseases Intelligence are those of the authors and not necessarily those of the Australian Government Department of Health or the Communicable Diseases Network Australia. Data may be subject to revision.

**Enquiries**Enquiries regarding any other use of this publication should be addressed to the Communication Branch, Department of Health, GPO Box 9848, Canberra ACT 2601, or via e-mail to: copyright@health.gov.au

**Communicable Diseases Network Australia**Communicable Diseases Intelligence contributes to the work of the Communicable Diseases Network Australia.
<http://www.health.gov.au/cdna>